Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B7 | P16662 | 1/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.41 |
| ▸ | CASR | P41180 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19354578 | 0.82 | UGT2B7 (0.52) | UGT2B7AOC3MMP9MEN1KMT2A | |
| SCHEMBL2956980 | 0.79 | UGT2B7 (0.61) | UGT2B7AOC3MMP9MEN1KMT2A | |
| SCHEMBL11672373 | 0.79 | UGT2B7 (0.61) | UGT2B7AOC3MMP9MEN1KMT2A | |
| SCHEMBL7055482 | 0.79 | UGT2B7 (0.61) | UGT2B7AOC3MMP9MEN1KMT2A | |
| SCHEMBL9572783 | 0.78 | AOC3 (0.47) | UGT2B7AOC3MMP9MEN1KMT2A | |
| SCHEMBL1753651 | 0.77 | UGT2B7 (0.59) | UGT2B7AOC3MMP9MEN1KMT2A | |
| SCHEMBL16970628 | 0.77 | HCAR2 (0.43) | KMT2AHIF1AADRA2AADRA2BADRA2C | |
| SCHEMBL16970750 | 0.77 | HCAR2 (0.43) | KMT2AHIF1AADRA2AADRA2BADRA2C | |
| SCHEMBL96935 | 0.77 | HCAR2 (0.43) | KMT2AHIF1AADRA2AADRA2BADRA2C | |
| SCHEMBL9373270 | 0.76 | CYP1A2 (0.45) | KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024075815-A1 | 8-HYDROXYQUINOLINE COMPOUND AND USE THEREOF | 国立大学法人大阪大学 | 2024-04-11 | — | — | WO | disclosed |
| CN-107531624-B | Pyrrolidine compounds | 住友化学株式会社 | 2020-10-02 | — | — | CN | disclosed |
| EP-3287440-B1 | PYRROLIDINE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2019-03-27 | — | — | EP | disclosed |
| US-10190009-B2 | Ink composition, ink jet recording method using same, and colored material | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2019-01-29 | — | — | US | disclosed |
| US-10040760-B2 | Pyrrolidine compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-08-07 | — | — | US | disclosed |
| US-20180127364-A1 | PYRROLIDINE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-05-10 | — | — | US | disclosed |
| EP-3287440-A1 | PYRROLIDINE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2018-02-28 | — | — | EP | disclosed |
| US-20160160065-A1 | INK COMPOSITION, INK JET RECORDING METHOD USING SAME, AND COLORED MATERIAL | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-3015516-A1 | INK COMPOSITION, INK JET RECORDING METHOD USING SAME, AND COLORED MATERIAL | Nippon Kayaku Kabushiki Kaisha (JP) | 2016-05-04 | — | — | EP | disclosed |
| US-7223755-B2 | Hydroxymorpholinone derivative and medicinal use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2007-05-29 | — | — | US | disclosed |
| US-20050176704-A1 | Hydroxymorpholinone derivative and medicinal use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-11 | — | — | US | disclosed |
| EP-1218336-A2 | MELANIN CONCENTRATING HORMONE ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001021577-A2 | MELANIN CONCENTRATING HORMONE ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-03-29 | — | — | WO | disclosed |
| EP-0562832-A1 | Indole and indazole derivatives, for the treatment and prophylaxis of cerebral disorders, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1993-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176704-A1 | Hydroxymorpholinone derivative and medicinal use thereof | CAPN1, OPRM1, CAPN2 | UGT2B7 1446/4885AOC3 2544/4885MMP9 719/4885 |
| US-20180127364-A1 | PYRROLIDINE COMPOUND | CAT, POLI, PPOX | UGT2B7 2742/4885AOC3 1257/4885MMP9 424/4885 |
| US-10040760-B2 | Pyrrolidine compound | CAT, POLI, PPOX | UGT2B7 2742/4885AOC3 1257/4885MMP9 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.